Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic impact of KMT2A-PTD in acute myeloid leukemia in the NGS era: a multicenter retrospective study.

Annals of hematology·2026
Same author

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

International journal of hematology·2026
Same author

Mesenteric AL Amyloidosis with Diffuse Calcifications: A Case Report and Review of the Literature.

Internal medicine (Tokyo, Japan)·2026
Same author

Dual-antigen recognition iPSC-derived CAR-T cells for B-cell malignancies: establishment of a COVID-19 vaccine synergy strategy.

Frontiers in cell and developmental biology·2026
Same author

Immunoprecipitation of Protein Complexes from Trypanosoma brucei.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Persistent COVID-19 in Patients With Hematological Malignancies: A Focused Review in the Omicron Era.

Clinical lymphoma, myeloma & leukemia·2025

Related Experiment Video

Updated: Sep 19, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Early Epcoritamab Administration Revives CAR-T Cells in Relapsed/Refractory B-Cell Lymphomas.

Kensuke Yanashima1, Yoshiki Furukawa1, Midori Ishii1

  • 1Department of Hematology Juntendo University School of Medicine Tokyo Japan.

Ejhaem
|June 18, 2025
PubMed
Summary
This summary is machine-generated.

Bispecific antibodies like epcoritamab can revive chimeric antigen receptor T-cell (CAR-T) therapy effectiveness in relapsed B-cell lymphoma. Early treatment boosts CAR-T cell numbers and function, potentially improving patient outcomes.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.0K

Related Experiment Videos

Last Updated: Sep 19, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.0K

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Bispecific antibodies demonstrate efficacy in relapsed/refractory B-cell lymphoma patients.
  • Chimeric antigen receptor T-cell (CAR-T) therapy is a key treatment option for these patients.
  • Understanding treatment dynamics after CAR-T failure is crucial.

Purpose of the Study:

  • To investigate the impact of epcoritamab on CAR-T cell kinetics and function in B-cell lymphoma patients who relapsed post-CAR-T therapy.
  • To assess the potential of bispecific antibodies to restore CAR-T cell activity.

Main Methods:

  • Peripheral blood samples were analyzed for CAR-T cell kinetics and functional markers.
  • In vivo analysis was performed pre- and post-epcoritamab infusion.
  • CAR copy numbers and expression of exhaustion/cytotoxicity markers were measured.

Main Results:

  • CAR copy numbers increased at relapse and further upon epcoritamab administration.
  • CAR-T exhaustion markers did not increase, indicating preserved function.
  • Perforin and granzyme B expression increased post-epcoritamab, suggesting enhanced cytotoxicity.

Conclusions:

  • Early administration of epcoritamab, without cytotoxic agents, can revive CAR-T cell numbers and cytotoxicity in relapsed B-cell lymphoma after CAR-T therapy.
  • This approach may lead to improved clinical outcomes for patients.
  • Bispecific antibodies represent a promising strategy to overcome CAR-T therapy resistance.